Who is sponsoring NCT01266993?

NCT01266993 is sponsored by GlaxoSmithKline.

What condition does NCT01266993 study?

NCT01266993 studies Infections, Meningococcal, Meningococcal Vaccines.

What drugs are being tested in NCT01266993?

Interventions: Nimenrix (GSK134612 vaccine), Menjugate.

What is the status of NCT01266993?

NCT01266993 is currently COMPLETED.

Last reviewed 2020-11-23 · How we verify

Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children

NCT01266993 PHASE3 COMPLETED Results posted

The purpose of the study is to evaluate the persistence of the immune response of GSK134612 vaccine up to 68 months after vaccination in the primary vaccination study (NCT number = NCT00674583) of 2 to 10 year old subjects. This study will also evaluate the safety and immunogenicity of a booster dose of GSK134612 vaccine subjects who were primed in the primary vaccination study with either GSK134612 vaccine or Menjugate®. This protocol posting deals with objectives \& outcome measures of the persistence and booster epochs. The objectives \& outcome measures of the primary epoch are presented in a separate protocol posting (NCT number = NCT00674583)

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE3
Status	COMPLETED
Enrolment	271
Start date	Mon Jan 03 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat May 17 2014 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Infections, Meningococcal
Meningococcal Vaccines

Interventions

Nimenrix (GSK134612 vaccine)
Menjugate

Countries

France, Germany